This document considers the risk of transmitting Creutzfeldt-Jakob disease (CJD) or variant CJD agents via the advanced therapy medicinal products.
Keywords: Creutzfeldt-Jakob disease, gene therapy, cell therapy and tissue engineering medicinal products, donor selection criteria, tissue and blood donation